triiodothyronine has been researched along with Shock, Cardiogenic in 4 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Shock, Cardiogenic: Shock resulting from diminution of cardiac output in heart disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 1270 patients with STEMI treated with percutaneous coronary intervention (PCI) were consecutively enrolled in our study." | 1.72 | The Association of Thyroid Hormones With Cardiogenic Shock and Prognosis in Patients with ST Segment Elevation Myocardial Infarction (STEMI) Treated with Primary PCI. ( Luo, S; Shen, J; Wang, L; Xiang, J; Xiang, Z; Xue, Y; Zhou, W; Zhu, Y, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, Y | 1 |
| Zhu, Y | 1 |
| Shen, J | 1 |
| Zhou, W | 1 |
| Xiang, J | 1 |
| Xiang, Z | 1 |
| Wang, L | 1 |
| Luo, S | 1 |
| Mantzoros, CS | 1 |
| Ravi, J | 1 |
| Klein, I | 1 |
| MacKerrow, SD | 1 |
| Osborn, LA | 1 |
| Levy, H | 1 |
| Eaton, RP | 1 |
| Economou, P | 1 |
4 other studies available for triiodothyronine and Shock, Cardiogenic
| Article | Year |
|---|---|
The Association of Thyroid Hormones With Cardiogenic Shock and Prognosis in Patients with ST Segment Elevation Myocardial Infarction (STEMI) Treated with Primary PCI.
Topics: Humans; Percutaneous Coronary Intervention; Prognosis; Shock, Cardiogenic; ST Elevation Myocardial I | 2022 |
Treatment of myxedema-associated cardiogenic shock.
Topics: Humans; Myxedema; Shock, Cardiogenic; Thyroxine; Triiodothyronine | 1993 |
Treatment of myxedema-associated cardiogenic shock.
Topics: Humans; Myxedema; Shock, Cardiogenic; Triiodothyronine; Ventricular Function, Left | 1993 |
Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine.
Topics: Administration, Oral; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Middle Age | 1992 |